REFERENCES
- Edelstein PH. Antimicrobial chemotherapy for Legionnaire's disease: time for a change. Ann Intern Med 1998; 129: 328–30.
- Albini E, Belluco G, Berton M, Schioppacassi G, Ungheri D. In vitro antibacterial activity of thiamphenicol gly-cinate acetylcysteinate against respiratory pathogens. Arzneim—Forsch/Drug Res 1999; 49: 533–537.
- Ravizzola G, Carenzi A, Manca N, Peretti P. In vitro antibacterial activity of thiamphenicol. Chemioterapia 1984; 3: 992–1005.
- Lombardi A, Drago L, De Vecchi E, Mombelli B, Gismondo MR. Antimicrobial activity of thiamphenicol glyci-nate acetylcysteinate and other drugs against Chlamydia pneumoniae. Arzneim-Forsch/Drug Res 2001; 51: 264–267.
- National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard Fifth edition. NCCLS document M7-A5. NCCLS: Wayne, Pennsylvania; 2000.
- King A. Recommendations for susceptibility tests on fas-tidious organisms and those requiring special handling. J Antimicrob Chemother 2001; 48 (suppl. 51): 77-80.
- Glupczynski Y, Yourassowsky E, Van Der Linden MP, Crokaert F. Susceptibility of Streptococcus pneumoniae to chloramphenicol and thiamphenicol. J Antimicrob Chemother 1983; 11: 488–489.
- Edelstein PH, Edelstein MA. In vitro activity of Ro 23-9424 against clinical isolates of species. Antimicrob Agents Chemother 1992; 36: 2559-2561.
- Laplassotte J, Brunaud M. Recherches expêrimentales sur thiophenicol. Activitê antibactêrienne, concentrations humorales, elimination. Comparaison avec le chloramphêni-col. Thêrapie 1961; 16: 101–108.